Roche购买Poseida治疗药物,价值高达15亿美元,用于加强细胞和基因疗法。 Roche buys Poseida Therapeutics for up to $1.5 billion to boost its cell and gene therapies.

Roche同意以最多15亿美元的价格购买Poseida治疗药物,目的是扩大其在异基因细胞治疗和遗传药物方面的组合。 Roche has agreed to acquire Poseida Therapeutics for up to $1.5 billion, aiming to expand its portfolio in allogeneic cell therapy and genetic medicines. Poseida创新的CAR-T疗法和遗传药物,特别是针对固态肿瘤和自体免疫疾病的药物,将纳入Roche的分部。 Poseida's innovative CAR-T therapies and genetic medicines, particularly for solid tumors and autoimmune diseases, will integrate into Roche's division. 这项交易价值为每股9美元,加上里程碑时每股4美元的潜在价值,预计将在2025年初结束。 The deal, valued at $9 per share plus a potential $4 per share upon milestones, is expected to close in early 2025.